TKI Therapy Investigated to Prevent Graft-Versus-Host Disease-Related Scleroderma
Scleroderma can often be a side effect of chronic graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation, as it occurs in 15.5% of chronic GVHD patients within five years. Patients are diagnosed with a condition known as sclerodermatous chronic GVHD (scGVHD) and are at…